FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2512798439> ?p ?o ?g. }

• W2512798439 endingPage "3187" @default.
• W2512798439 startingPage "3187" @default.
• W2512798439 abstract "Abstract Background: The well-described prognostic impact of tumor characteristics and biology in multiple myeloma (MM), such as the combination of cytogenetics, the International Staging System (ISS) and lactate dehydrogenase (LDH, Moreau et. al., JCO, 2014) as well as frailty (Palumbo et al., Blood, 2015) significantly influence patient outcomes. However, only limited data on the impact of infections during therapy exist (Rajkumar et al., Lancet Oncology, 2010). Therefore, we hypothesized that severe infections during induction therapy (IT) in transplant-eligible MM influence dosage of therapies, treatment responses after IT and survival. Patients and Methods: From 05/2005 until 05/2008, 399 patients were randomly assigned to receive IT with either three cycles of VAD (vincristine, VIN, i.v. 0.4mg, days 1-4; doxorubicine, DOXO, i.v. 9mg/m2, days 1-4; dexamethasone, DEX, p.o. 40mg, days 1-4, 9-12, 17-20; n=201, arm A) or PAD (bortezomib, BTZ, i.v. 1.3mg/m2, days 1, 4, 8, 11; DOXO i.v. 9mg/m2, days 1-4; DEX p.o. 40mg, days 1-4, 9-12, 17-20; n=194, arm B), followed by high-dose melphalan (HDM) and autologous stem cell transplantation (ASCT) and either thalidomide (arm A) or bortezomib (arm B) maintenance within the German part of the joint GMMG-HD4/HOVON65 trial (Sonneveld et al., JCO, 2012). After exclusion of ineligible patients, 395 patients (99.0%) were evaluable for analyses. Any severe infection (equal or greater grade 3, according to the Common Terminology Criteria for Adverse Events, Version 4.0) during IT (at least once, defined from first until last date of application of IT medication) occurred in 105 patients (VAD n=53/198 and PAD n=52/192, 26.9% of all patients, missing data n=5). Results: Among patients with a severe infection during IT in the VAD and PAD arms, total DEX and DOXO doses (equal dosage in VAD/PAD group) were significantly lower (median DEX dose (mg/m2): 689.0 [77.7, 1014.1] vs. 742.3 [0.0, 1324.1], p<0.001 and median DOXO dose (mg/m2): 106.9 [33.0, 115.4] vs. 107.6 [27.6, 149.5], p<0.001). Accordingly, the BTZ dose during IT in the PAD group was significantly lower in patients with severe infections (median BTZ dose (mg/m2): 15.1 [5.1, 16.6] vs. 15.5 [1.3, 16.4], p<0.001). Combined PAD and VAD very good partial response rates or better (VGPR+) after IT were 27.6% vs. 19.9% (p=0.12) for patients with or without a severe infection during IT. Overall survival (OS) was significantly shortened in patients with at least one severe infection during IT (median OS: 81.8 months vs. not reached, p=0.04, Figure 1A). OS plots diverged in the early period of observation (< 3 months), driven by infection-related deaths (n=8). A landmark analysis 3 months after registration demonstrated approximated survival curves without significant differences in OS (median OS: 78.8 months vs. not reached, p=0.30, Figure 1B). Similarly, progression-free survival (PFS) was shortened, though not significantly (median PFS: 30.2 vs. 35.0 months, p=0.08). However, since not just death accounts as PFS event, the impact of infection-related deaths on PFS remains smaller than on OS. Accordingly, landmark analyses after 3 months from registration showed again closer survival curves (median PFS: 28.5 vs. 32.4 months, p=0.36). Conclusions: Severe infections have a critical impact on the applied doses of IT and outcome in the early, vulnerable phases of MM therapy. OS for transplant-eligible MM patients with severe infections during IT was significantly shortened, mainly driven by early infection-related deaths (< 3 months). A reduction of DEX doses during PAD/PAd IT in the subsequent GMMG study generation (GMMG-HD4/HOVON65: 480mg/cycle to GMMG-MM5: 240mg/cycle) and the recommendation of antibiotic/antiviral prophylaxis throughout the whole IT led to a reduced rate of severe infections of 12% (PAd) in the GMMG-MM5 trial. Further analyses are needed to elucidate how severe infections can be avoided, and whether there is an overlap between the subgroup of patients with severe infections during IT and patients with known adverse prognostic factors or reduced fitness/pre-existing conditions. (A) Overall survival and (B) landmark analysis on overall survival 3 months after start of induction therapy of patients with or without at least one severe infection (equal or greater grade 3) during induction therapy. Figure 1. Impact of severe infections on overall survival. Figure 1. Impact of severe infections on overall survival. Disclosures Mai: Janssen-Cilag: Other: Travel Grant; Onyx: Other: Travel Grant; Mundipharma: Other: Travel Grant; Celgene: Other: Travel Grant. Salwender:Celgene: Honoraria; Janssen Cilag: Honoraria; Bristol Meyer Sqibb: Honoraria; Amgen: Honoraria; Novartis: Honoraria. Pfreundschuh:Roche: Honoraria; Amgen, Roche, Spectrum: Research Funding; Boehringer Ingelheim, Celegene, Roche, Spectrum: Other: Advisory board. Duehrsen:Janssen: Honoraria. Hillengass:Janssen-Cilag: Honoraria, Other: Travel support; Celgene: Honoraria, Other: Travel support; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Other: Travel support; Sanofi: Research Funding. Scheid:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees. Weisel:BMS: Consultancy, Honoraria, Other: Travel Support; Onyx: Consultancy, Honoraria; Janssen Pharmaceuticals: Consultancy, Honoraria, Other: Travel Support, Research Funding; Celgene: Consultancy, Honoraria, Other: Travel Support, Research Funding; Amgen: Consultancy, Honoraria, Other: Travel Support; Novartis: Other: Travel Support; Noxxon: Consultancy. Blau:MSD: Honoraria; Celgene: Honoraria, Research Funding; AMGEN: Honoraria; JAZZ pharm: Honoraria; BMS: Honoraria; Shire: Honoraria; Baxalta: Honoraria; Janssen: Honoraria, Research Funding. Goldschmidt:Onyx: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Millenium: Honoraria, Research Funding, Speakers Bureau; Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Chugai: Honoraria, Research Funding, Speakers Bureau." @default.
• W2512798439 created "2016-09-16" @default.
• W2512798439 creator A5014277422 @default.
• W2512798439 creator A5018364683 @default.
• W2512798439 creator A5019564821 @default.
• W2512798439 creator A5022522496 @default.
• W2512798439 creator A5030025370 @default.
• W2512798439 creator A5047272364 @default.
• W2512798439 creator A5051124529 @default.
• W2512798439 creator A5053168954 @default.
• W2512798439 creator A5059718263 @default.
• W2512798439 creator A5060295441 @default.
• W2512798439 creator A5062881120 @default.
• W2512798439 creator A5064702344 @default.
• W2512798439 creator A5068472643 @default.
• W2512798439 creator A5075453602 @default.
• W2512798439 creator A5075621940 @default.
• W2512798439 creator A5087348033 @default.
• W2512798439 creator A5088234793 @default.
• W2512798439 date "2015-12-03" @default.
• W2512798439 modified "2023-10-03" @default.
• W2512798439 title "Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4" @default.
• W2512798439 doi "https://doi.org/10.1182/blood.v126.23.3187.3187" @default.
• W2512798439 hasPublicationYear "2015" @default.
• W2512798439 type Work @default.
• W2512798439 sameAs 2512798439 @default.
• W2512798439 citedByCount "0" @default.
• W2512798439 crossrefType "journal-article" @default.
• W2512798439 hasAuthorship W2512798439A5014277422 @default.
• W2512798439 hasAuthorship W2512798439A5018364683 @default.
• W2512798439 hasAuthorship W2512798439A5019564821 @default.
• W2512798439 hasAuthorship W2512798439A5022522496 @default.
• W2512798439 hasAuthorship W2512798439A5030025370 @default.
• W2512798439 hasAuthorship W2512798439A5047272364 @default.
• W2512798439 hasAuthorship W2512798439A5051124529 @default.
• W2512798439 hasAuthorship W2512798439A5053168954 @default.
• W2512798439 hasAuthorship W2512798439A5059718263 @default.
• W2512798439 hasAuthorship W2512798439A5060295441 @default.
• W2512798439 hasAuthorship W2512798439A5062881120 @default.
• W2512798439 hasAuthorship W2512798439A5064702344 @default.
• W2512798439 hasAuthorship W2512798439A5068472643 @default.
• W2512798439 hasAuthorship W2512798439A5075453602 @default.
• W2512798439 hasAuthorship W2512798439A5075621940 @default.
• W2512798439 hasAuthorship W2512798439A5087348033 @default.
• W2512798439 hasAuthorship W2512798439A5088234793 @default.
• W2512798439 hasConcept C126322002 @default.
• W2512798439 hasConcept C141071460 @default.
• W2512798439 hasConcept C197934379 @default.
• W2512798439 hasConcept C2776063141 @default.
• W2512798439 hasConcept C2776364478 @default.
• W2512798439 hasConcept C2776694085 @default.
• W2512798439 hasConcept C2776755627 @default.
• W2512798439 hasConcept C2777063308 @default.
• W2512798439 hasConcept C2777478702 @default.
• W2512798439 hasConcept C2777793932 @default.
• W2512798439 hasConcept C2778496288 @default.
• W2512798439 hasConcept C2778684742 @default.
• W2512798439 hasConcept C2779429289 @default.
• W2512798439 hasConcept C2779609412 @default.
• W2512798439 hasConcept C2911091166 @default.
• W2512798439 hasConcept C71924100 @default.
• W2512798439 hasConcept C90924648 @default.
• W2512798439 hasConceptScore W2512798439C126322002 @default.
• W2512798439 hasConceptScore W2512798439C141071460 @default.
• W2512798439 hasConceptScore W2512798439C197934379 @default.
• W2512798439 hasConceptScore W2512798439C2776063141 @default.
• W2512798439 hasConceptScore W2512798439C2776364478 @default.
• W2512798439 hasConceptScore W2512798439C2776694085 @default.
• W2512798439 hasConceptScore W2512798439C2776755627 @default.
• W2512798439 hasConceptScore W2512798439C2777063308 @default.
• W2512798439 hasConceptScore W2512798439C2777478702 @default.
• W2512798439 hasConceptScore W2512798439C2777793932 @default.
• W2512798439 hasConceptScore W2512798439C2778496288 @default.
• W2512798439 hasConceptScore W2512798439C2778684742 @default.
• W2512798439 hasConceptScore W2512798439C2779429289 @default.
• W2512798439 hasConceptScore W2512798439C2779609412 @default.
• W2512798439 hasConceptScore W2512798439C2911091166 @default.
• W2512798439 hasConceptScore W2512798439C71924100 @default.
• W2512798439 hasConceptScore W2512798439C90924648 @default.
• W2512798439 hasIssue "23" @default.
• W2512798439 hasLocation W25127984391 @default.
• W2512798439 hasOpenAccess W2512798439 @default.
• W2512798439 hasPrimaryLocation W25127984391 @default.
• W2512798439 hasRelatedWork W168240859 @default.
• W2512798439 hasRelatedWork W1998735674 @default.
• W2512798439 hasRelatedWork W2106101491 @default.
• W2512798439 hasRelatedWork W2136773918 @default.
• W2512798439 hasRelatedWork W2152579684 @default.
• W2512798439 hasRelatedWork W2154021003 @default.
• W2512798439 hasRelatedWork W2400769328 @default.
• W2512798439 hasRelatedWork W2403269090 @default.
• W2512798439 hasRelatedWork W2512798439 @default.
• W2512798439 hasRelatedWork W2944892461 @default.
• W2512798439 hasVolume "126" @default.
• W2512798439 isParatext "false" @default.
• W2512798439 isRetracted "false" @default.
• W2512798439 magId "2512798439" @default.
• W2512798439 workType "article" @default.